Merus (NASDAQ:MRUS) Rating Downgrade

In analysts note shared with investors on Tuesday morning, Citigroup decreased shares of Merus (NASDAQ:MRUS) to Neutral rating from Buy rating.

This stock rating downgrade is noticed by stock speculators, as NASDAQ:MRUS is right now trading -8.23% lower at $26.16 as of 4:00 AM New York time. Merus’s stock is 0% over the last 200 days. It has underperformed the S&P500, which has increased 12.74% over the same time period.

According to data compiled by Thomson Reuters, Merus (NASDAQ:MRUS)’s stock is covered by 4 equity analysts across the Street, with 0 analysts giving it a Sell rating, 0 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $16.28, which reflects an downside potential of 37.77% over the current price.

Merus (NASDAQ:MRUS) Profile

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format.

Merus (NASDAQ:MRUS) traded down -8.23% on 21 March, hitting $26.16. A total of 42,171 shares of the company’s stock traded hands. This is down from average of 65,609 shares. Merus has a 52 week low of $7.26 and a 52 week high of $33.63. The company has a market cap of $383.12M and a P/E ratio of 0.

Get the latest Merus (NASDAQ:MRUS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Citigroup Lowers Merus (NASDAQ:MRUS) to Neutral From Buy Rating appeared first on Octafinance.